What is GPB Scientific?
Founded in 2002, GPB Scientific occupies a critical niche in the life sciences sector by addressing the bottlenecks inherent in cell therapy production. The company has engineered a high-throughput, automatable, microfluidic closed-system designed to replace labor-intensive manual enrichment processes such as centrifugation and magnetic separation. By enabling point-of-collection leukapheresis sample preparation, GPB Scientific is positioning itself as a foundational player in the push toward seven-day therapeutic dosing, a milestone that could drastically improve patient outcomes and operational efficiency in oncology treatment centers.
How much funding has GPB Scientific raised?
GPB Scientific has raised a total of $47.7M across 6 funding rounds:
Private Equity
$1.9M
Private Equity
$1.4M
Debt
$810K
Other Financing Round
$25.5M
Debt
$150K
Unspecified
$18M
Private Equity (2013): $1.9M, investors not publicly disclosed
Private Equity (2016): $1.4M, investors not publicly disclosed
Debt (2017): $810K, investors not publicly disclosed
Other Financing Round (2020): $25.5M featuring Vensana Capital and Amgen Business Development
Debt (2020): $150K backed by PPP
Unspecified (2021): $18M with participation from Vensana Capital Management and Amgen Ventures
Key Investors in GPB Scientific
Vensana Capital Management
Vensana Capital is a venture capital and growth equity investment firm focused on partnering with entrepreneurs to drive innovation in healthcare through medical technology.
Amgen Business Development
Amgen Oncology is dedicated to transforming cancer treatment through innovative therapies and a commitment to patient care, focusing on high-quality biosimilar medicines.
Amgen Ventures
The corporate venture arm of Amgen, focusing on strategic investments in early-stage companies that align with the firm's long-term goals in biotechnology and therapeutic innovation.
What's next for GPB Scientific?
The recent capital injection is expected to accelerate the transition of GPB Scientific's technology from validated research applications to a fully realized, turnkey commercial system. As the company scales, the focus will likely shift toward regulatory milestones and the integration of its microfluidic platforms into existing clinical manufacturing pipelines. By eliminating manual intervention, GPB Scientific is well-positioned to capture significant market share in the rapidly expanding cell therapy landscape, where speed and purity are the primary drivers of competitive advantage and clinical success.
See full GPB Scientific company page
